{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:27:40Z","timestamp":1793766460399,"version":"4.6.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,9,18]],"date-time":"2027-09-18T00:00:00Z","timestamp":1821225600000},"content-version":"am","delay-in-days":352,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clgc.2026.102614","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:21:52Z","timestamp":1783178512000},"page":"102614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing"],"prefix":"10.1016","volume":"24","author":[{"given":"Shuichi","family":"Tatarano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8480-9100","authenticated-orcid":false,"given":"Kouji","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Mita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0954-3995","authenticated-orcid":false,"given":"Takehiko","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ippei","family":"Chikazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2257-3892","authenticated-orcid":false,"given":"Noriyasu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Fukagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Shigehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuko","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102614_bib0001","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2026.102614_bib0002","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/jjco\/hyv002","article-title":"An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013","volume":"45","author":"Katanoda","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102614_bib0003","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102614_bib0004","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2026.102614_bib0005","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102614_bib0006","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102614_bib0007","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.28444","article-title":"Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer","volume":"7","author":"La","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102614_bib0008","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2022.04.016","article-title":"Enzalutamide versus Abiraterone plus prednisolone before chemotherapy for castration-resistant prostate cancer: a multicenter randomized controlled trial","volume":"41","author":"Izumi","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102614_bib0009","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/pros.24796","article-title":"Dose modification in enzalutamide and abiraterone plus prednisolone for castration-resistant prostate cancer: a subanalysis from the ENABLE study for PCa","volume":"85","author":"Tanaka","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2026.102614_bib0010","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/s12885-017-3661-2","article-title":"Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial","volume":"17","author":"Izumi","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2026.102614_bib0011","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3390\/cancers16030508","article-title":"Enzalutamide versus Abiraterone plus Prednisolone for nonmetastatic castration-resistant prostate cancer: a sub-analysis from the ENABLE study for PCa","volume":"16","author":"Mita","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2026.102614_bib0012","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/pros.24897","article-title":"Efficacy and safety of Enzalutamide and abiraterone plus prednisolone in elder castration-resistant prostate cancer patients: a sub-analysis from the ENABLE study","volume":"85","author":"Okamura","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2026.102614_bib0013","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102614_bib0014","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","article-title":"Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales","volume":"24","author":"Cella","year":"2002","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clgc.2026.102614_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54253","article-title":"Androgen receptor pathway inhibitor therapy for advanced prostate cancer: secondary analysis of a randomized clinical trial","volume":"8","author":"Bastos","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2026.102614_bib0016","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/pros.24514","article-title":"A prospective study of the relationship between CRPC patient's quality of life after enzalutamide and serum testosterone levels measured via LC-MS\/MS","volume":"83","author":"Miyazawa","year":"2023","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2026.102614_bib0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.euros.2021.05.003","article-title":"A prospective study of the relationship between clinical outcomes after enzalutamide and serum androgen levels measured via liquid chromatography-tandem mass spectrometry in patients with castration-resistant prostate cancer","volume":"29","author":"Miyazawa","year":"2021","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.clgc.2026.102614_bib0018","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2004.03.025","article-title":"How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the Quality-of-life questionnaire C30","volume":"22","author":"Fromme","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2026.102614_bib0019","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s11136-011-0031-4","article-title":"Reliability of adverse symptom event reporting by clinicians","volume":"21","author":"Atkinson","year":"2012","journal-title":"Qual Life Res"},{"key":"10.1016\/j.clgc.2026.102614_bib0020","doi-asserted-by":"crossref","first-page":"4882","DOI":"10.1158\/1078-0432.CCR-25-1918","article-title":"FDA-AACR strategies for optimizing dosages for oncology drug products: early-phase trials using innovative trial designs and biomarkers","volume":"31","author":"Okusanya","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102614_bib0021","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S1470-2045(24)00648-X","article-title":"Dose optimisation to improve access to effective cancer medicines","volume":"26","author":"Tannock","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2026.102614_bib0022","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10549-022-06755-5","article-title":"Patient-centered dosing: oncologists' perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)","volume":"196","author":"Loeser","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clgc.2026.102614_bib0023","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1200\/OP.23.00539","article-title":"The right dose: results of a patient advocate-led survey of individuals with metastatic breast cancer regarding treatment-related side effects and views about dosage assessment to optimize quality of life","volume":"20","author":"Loeser","year":"2024","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.clgc.2026.102614_bib0024","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1111\/cas.12496","article-title":"Phase-1 study of abiraterone acetate in chemotherapy-naive Japanese patients with castration-resistant prostate cancer","volume":"105","author":"Matsubara","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clgc.2026.102614_bib0025","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00280-014-2616-4","article-title":"Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing","volume":"75","author":"Inoue","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2026.102614_bib0026","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00280-012-1865-3","article-title":"Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men","volume":"69","author":"Acharya","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2026.102614_bib0027","first-page":"1","article-title":"Integration of palliative and supportive care into the management of genitourinary malignancies","volume":"42","author":"Saraiya","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600114X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155876732600114X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:16:59Z","timestamp":1793765819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155876732600114X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S155876732600114X"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102614","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality-of-Life in CRPC Patients Treated With Enzalutamide Versus Abiraterone: Impact of Standard and Modified Dosing","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102614"}}